Sumit Gupta1, Smita Bhatia. 1. aDivision of Haematology/Oncology, Hospital for Sick Children bFaculty of Medicine, Institute of Health Policy, Management, and Evaluation, and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada cInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama, USA.
Abstract
PURPOSE OF REVIEW: Outcomes for children with cancer have improved dramatically. Although the contribution of disease biology and therapy resistance to treatment failure continues to be a focus of intense research efforts, the role of medication nonadherence on the part of caregivers or patients has been relatively neglected. Efforts to further improve childhood cancer cure rates must include a focus on improving medication adherence. RECENT FINDINGS: Recent studies in children with acute lymphoblastic leukemia have conclusively demonstrated that nonadherence to oral antimetabolite therapy is associated with a significant increase in relapse risk. The impact of nonadherence to other oral medications in acute lymphoblastic leukemia and in other childhood cancers remains unknown. Tools by which clinicians can accurately identify nonadherent families are currently being developed but remain suboptimal. Similarly, while current efforts to develop interventions aimed at increasing adherence rates are underway, their feasibility and effectiveness is still unknown. SUMMARY: Future studies must focus on the development and widespread implementation of methods by which to identify and minimize nonadherence. Doing so will allow for further improve childhood cancer cure outcomes.
PURPOSE OF REVIEW: Outcomes for children with cancer have improved dramatically. Although the contribution of disease biology and therapy resistance to treatment failure continues to be a focus of intense research efforts, the role of medication nonadherence on the part of caregivers or patients has been relatively neglected. Efforts to further improve childhood cancer cure rates must include a focus on improving medication adherence. RECENT FINDINGS: Recent studies in children with acute lymphoblastic leukemia have conclusively demonstrated that nonadherence to oral antimetabolite therapy is associated with a significant increase in relapse risk. The impact of nonadherence to other oral medications in acute lymphoblastic leukemia and in other childhood cancers remains unknown. Tools by which clinicians can accurately identify nonadherent families are currently being developed but remain suboptimal. Similarly, while current efforts to develop interventions aimed at increasing adherence rates are underway, their feasibility and effectiveness is still unknown. SUMMARY: Future studies must focus on the development and widespread implementation of methods by which to identify and minimize nonadherence. Doing so will allow for further improve childhood cancer cure outcomes.
Authors: K R Schultz; A Carroll; N A Heerema; W P Bowman; A Aledo; W B Slayton; H Sather; M Devidas; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta Journal: Leukemia Date: 2014-01-20 Impact factor: 11.528
Authors: Wendy Landier; Cynthia B Hughes; Evelyn R Calvillo; Nancy L R Anderson; Deborah Briseño-Toomey; Leticia Dominguez; Alex M Martinez; Cara Hanby; Smita Bhatia Journal: J Pediatr Oncol Nurs Date: 2011-06-08 Impact factor: 1.636
Authors: Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Smita Bhatia; Wendy Landier; Lindsey Hageman; Heeyoung Kim; Yanjun Chen; Kristine R Crews; William E Evans; Bruce Bostrom; Jacqueline Casillas; David S Dickens; Kelly W Maloney; Joseph P Neglia; Yaddanapudi Ravindranath; A Kim Ritchey; F Lennie Wong; Mary V Relling Journal: Blood Date: 2014-05-14 Impact factor: 22.113
Authors: Yelena P Wu; David D Stenehjem; Lauri A Linder; Bin Yu; Bridget Grahmann Parsons; Ryan Mooney; Mark N Fluchel Journal: J Pediatr Oncol Nurs Date: 2017-11-30 Impact factor: 1.636
Authors: Yelena P Wu; Lauri A Linder; Patsaporn Kanokvimankul; Brynn Fowler; Bridget G Parsons; Catherine F Macpherson; Rebecca H Johnson Journal: Oncol Nurs Forum Date: 2018-01-01 Impact factor: 2.172
Authors: Elizabeth G Bouchard; Leonard H Epstein; Hital Patel; Paula C Vincent; Susan A LaValley; Julia A Devonish; Jessica Wadium; Xiaozhong Wen; Kara M Kelly Journal: Pediatr Hematol Oncol Date: 2022-02-10 Impact factor: 2.070
Authors: Alexandra M Psihogios; Lisa A Schwartz; Kylie B Ewing; Bryn Czerniecki; Leslie S Kersun; Ahna L H Pai; Janet A Deatrick; Lamia P Barakat Journal: J Adolesc Young Adult Oncol Date: 2020-05-11 Impact factor: 2.223
Authors: Alexandra M Psihogios; Mashfiqui Rabbi; Annisa Ahmed; Elise R McKelvey; Yimei Li; Jean-Philippe Laurenceau; Stephen P Hunger; Linda Fleisher; Ahna Lh Pai; Lisa A Schwartz; Susan A Murphy; Lamia P Barakat Journal: JMIR Res Protoc Date: 2021-10-22